Cancer Genetics, Inc. (NASDAQ:CGIX) just came public on April 10, 2013 and raised roughly $62 million through two stock offerings. The company's primary objective is to be a leader in development and commercialization of proprietary genomic tests and services. Given their recent equity offerings, the company is now in a great position to implement their growth strategy. Management has set reasonable growth targets for their business, which could generate substantial revenue growth over the next several years, I believe revenues could grow from the current $7M FY2013 to over $50M by FY2015 and earnings could approach $0.90 to $1.00. I believe the stock could approach $30 by sometime in 2015.
Alan Mertz, president of the American Clinical Laboratory...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|